Repairing the brain : Gene therapy
(2018) In Journal of Parkinson's Disease 8(s1). p.123-130- Abstract
In vivo gene therapy for neurodegenerative disorders has turned out to be a formidable challenge. It is a field not much older than twenty years, but we were many who would have predicted a much easier path towards the clinic using this treatment modality. For Parkinson's disease patients, this has meant a frustrating wait, seeing many promising therapies being forgotten after a few pre-clinical proof-of-concept studies. The reasons for this are both scientific and economical. However, this is slowly but surely changing and over the next two decades we will see a very exciting development in this field. In a foreseeable future, gene therapy will be a very natural component of many clinical therapies, not least in Parkinson's disease.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1f4d64d9-6866-4d69-a503-9255deefb78b
- author
- Björklund, Tomas LU
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Clinical trial, Dependovirus, Gene editing, Genetic therapy, Neuroprotection, Parkinson's disease, Rejuvenation
- in
- Journal of Parkinson's Disease
- volume
- 8
- issue
- s1
- pages
- 123 - 130
- publisher
- IOS Press
- external identifiers
-
- pmid:30584164
- scopus:85058849634
- ISSN
- 1877-7171
- DOI
- 10.3233/JPD-181485
- language
- English
- LU publication?
- yes
- id
- 1f4d64d9-6866-4d69-a503-9255deefb78b
- alternative location
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311375/
- date added to LUP
- 2019-01-08 12:39:40
- date last changed
- 2024-03-18 22:43:23
@article{1f4d64d9-6866-4d69-a503-9255deefb78b,
abstract = {{<p>In vivo gene therapy for neurodegenerative disorders has turned out to be a formidable challenge. It is a field not much older than twenty years, but we were many who would have predicted a much easier path towards the clinic using this treatment modality. For Parkinson's disease patients, this has meant a frustrating wait, seeing many promising therapies being forgotten after a few pre-clinical proof-of-concept studies. The reasons for this are both scientific and economical. However, this is slowly but surely changing and over the next two decades we will see a very exciting development in this field. In a foreseeable future, gene therapy will be a very natural component of many clinical therapies, not least in Parkinson's disease.</p>}},
author = {{Björklund, Tomas}},
issn = {{1877-7171}},
keywords = {{Clinical trial; Dependovirus; Gene editing; Genetic therapy; Neuroprotection; Parkinson's disease; Rejuvenation}},
language = {{eng}},
number = {{s1}},
pages = {{123--130}},
publisher = {{IOS Press}},
series = {{Journal of Parkinson's Disease}},
title = {{Repairing the brain : Gene therapy}},
url = {{http://dx.doi.org/10.3233/JPD-181485}},
doi = {{10.3233/JPD-181485}},
volume = {{8}},
year = {{2018}},
}